Don't want ads? Subscribe or login now.

Pharma Co. Brass Face Investor Suit Over Drug Trial Probe

By Emilie Ruscoe · December 13, 2024, 7:53 PM EST

Officers and directors of cancer treatment developer MacroGenics Inc. have been hit with a shareholder derivative action alleging they breached their fiduciary duties after the company announced three study participant deaths...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Cottle v. Macrogenics, Inc. et al

Case Number

8:24-cv-03578

Court

Maryland

Nature of Suit

Securities/Commodities

Date Filed

December 11, 2024

Recent Articles By Emilie

October 28, 2025
Ex-Philips CEO Can't Undo Finding He Misled Shareholders
October 27, 2025
Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud
October 17, 2025
Sana Biotech Fights Investor Fraud Claims Over Trial Data
October 09, 2025
Tivity Health Investors Seek Final OK Of $17M Settlement
October 06, 2025
2 Firms To Lead Humana Investor Suit Over Post-COVID Costs
September 16, 2025
BrainStorm Can't Shed Investors' ALS Treatment Trial Claims
September 11, 2025
Dental Supply Co.'s $84M Price-Fixing Deal Gets Final OK
August 28, 2025
Telehealth Co. Faces Investor Suit Over Revenue Reversal
August 22, 2025
Ex-Pharma Exec Leaked Bankruptcy Deliberations, Suit Says
August 20, 2025
Northwell Health Inks $2.75M Deal In 403(B) Suit